Eli Lilly & Co. (LLY) on Wednesday unveiled a series of management changes spurred by the departures of a pair of executives.
The Indianapolis drug maker said Darren Carroll, senior vice president of corporate business development, will retire at the end of the month. Mr. Carroll, who has led the corporate business development organization for nearly a decade, oversaw the recent $8.1 billion acquisition of Loxo Oncology–the largest acquisition in Lilly’s history.
Eli Lilly said Phil Johnson, currently senior vice president and treasurer, will assume additional oversight of merger-and-acquisition activity. The company said it named Heather Wasserman vice president of corporate business development, with responsibility for business development transactions, emerging technologies and innovation, and venture capital.
Eli Lilly also said Levi Garraway has resigned as senior vice president of oncology research and early-phase development to pursue other opportunities. The company said Josh Bilenker, chief executive of Loxo, will lead oncology research and early-phase development on an interim basis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.